Potential drug for treating chronic pain with few side effects

July.28.2017RESEARCH HIGHLIGHTS

Okayama University Medical Research Updates (OU-MRU) 2017.07 Vol.42

Source: Okayama University (JAPAN), Public Relations and Information Strategy
For immediate release: 28 July 2017
Okayama University research: Potential drug for treating chronic pain with few side effects

(Okayama, 28 July) Researchers at Okayama University describe in Proceedings of the National Academy of Sciences the effect of clodronate on the regulation of adenosine triphosphate release and its potential as a drug for the treatment of chronic pain. The compound has few side effects and may also be effective for treating other medical conditions including diabetes.

Typical drugs for treating chronic pain — a condition estimated to affect 20 – 25% of the world’s population — often cause serious side effects such as stomach problems, kidney failure or addiction. Now, a team of researchers led by Yuri Kato and Takaaki Miyaji from Okayama University has identified a compound, clodronate, that inhibits the mechanism triggering chronic pain while having few side effects. Clodronate may therefore be used for future chronic pain drug development. Moreover, the researchers reckon it may also be effective for the treatment of other diseases such as diabetes and neurological disorders.

Acute pain is the result of sensory nerves responding to a (potentially) harmful stimulus, a biological process called nociception. However, inflammation or nerve injuries can trigger pathological nociception — a long-lasting sensation of pain due to the stimulated production of adenosine triphosphate (ATP) molecules that bind to so-called purinergic receptors causing pain responses. The ATP molecules participating in the purinergic signalling processes are carried by vesicular nucleotide transporter (VNUT) protein. Since it is known that suppression of VNUT function leads to an improvement of neuropathological conditions in mice, Moriyama and Miyaji and colleagues looked for a VNUT inhibitor with few side effects.

The researchers tested clodronate, a molecule belonging to the class of bisphosphonates, compounds used for treating osteoporosis. Clodronate does not contain nitrogen, a characteristic known to decrease therapeutic effect for osteoporosis and the number of side effects. Experiments on proteoliposomes showed that clodronate is a potent inhibitor of VNUT, whereas injections of clodronate in wild-type mice showed that it attenuated chronic neuropathic and inflammatory pain.

Background
Chronic pain
In medicine, pain lasting a long time — typically, 3 months or more — is called chronic, as opposed to acute pain. Chronic pain can be neuropathic, when the nervous system is damaged, or nociceptive, when inflammation causes nociceptors (pain sensors) to be triggered permanently.
Current drugs for the treatment of chronic pain, notably opioids like morphine, have various side effects, including stomach or kidney dysfunction, drug addiction, drowsiness and vomiting. Yuri Kato and Takaaki Miyaji and colleagues have now identified a potential non-opioid drug, clodronate, that suppresses chronic pain by inhibiting the release of adenosine triphosphate (ATP), a mechanism involved in chronic pain.

Purinergic signalling
In living organisms, purinergic signalling is a way of passing on signals outside cells. It involves purines, particular types of aromatic molecules containing nitrogen, and so-called purinergic receptors in cells. The purinergic signalling mechanism associated with chronic pain involves the purine adenosine triphosphate (ATP), a molecule playing an important role in biological energy transfer processes; ATP is carried by vesicular nucleotide transporter (VNUT) protein. The present study shows that clodronate inhibits VNUT, which in turn attenuates neuropathic and nociceptive pain. Since clodronate has few side effects and since it has already been clinically approved in many countries, it is a promising drug for the treatment of chronic pain.

Caption
Clodronate-evoked inhibition of vesicular ATP release is important for the treatment of chronic pain.

Reference
Yuri Kato, Miki Hiasa, Reiko Ichikawa, Nao Hasuzawa, Atsushi Kadowaki, Ken Iwatsuki, Kazuhiro Shima, Yasuo Endo, Yoshiro Kitahara, Tsuyoshi Inoue, Masatoshi Nomura, Hiroshi Omote, Yoshinori Moriyama & Takaaki Miyaji. Identification of a vesicular ATP release inhibitor for the treatment of neuropathic and inflammatory pain. Proceedings of the National Academy of Sciences, August 1, vol.114, no.31, 2017. DOI: 10.1073/pnas.1704847114.
http://www.pnas.org/content/early/2017/07/17/1704847114.abstract

Correspondence to
Associate Professor Takaaki Miyaji, Ph.D.
Advanced Science Research Center, Okayama University,
Tsushima-naka 1-1-1, Okayama city, Okayama 700-8530,
Japan
E-mail: miyaji-t@okayama-u.ac.jp
http://www.okayama-u.ac.jp/user/grcweb/asrc_e.html

Further information
Okayama University
1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
Public Relations and Information Strategy
E-mail: www-adm@adm.okayama-u.ac.jp
Website: http://www.okayama-u.ac.jp/index_e.html
Okayama Univ. e-Bulletin: http://www.okayama-u.ac.jp/user/kouhou/ebulletin/
About Okayama University (YouTube):
https://www.youtube.com/watch?v=iDL1coqPRYI
Okayama University Image Movie (YouTube):
https://www.youtube.com/watch?v=KU3hOIXS5kk

 



Associate Professor Takaaki Miyaji

ACADEMIC YEAR